However, data on the effects of SGLT2 inhibitors on subclinical vascular disease, including arterial stiffness, carotid atherosclerosis and peripheral arterial disease (PAD) are conflicting and limited [12,13,14,15,16]. This evidence concerns the gene SLC5A2 and carotid atherosclerosis.